Under the partnership deal, Patheon will possess rights to market Procaps’ soft gel technology and manufacturing capabilities in North America, Europe and Asia.
Patheon CEO Jim Mullen said by integrating Procaps’manufacturing capabilities and proprietary technology with its global experience, the company can provide customers with royalty-free soft gel capsule solutions for their products.
The soft-gel product will be branded as "P-Gels", and offers rapid and consistent absorption of drugs and consistent delivery of highly potent drugs that require small dosages.
Corporate Development and Strategy & General Counsel executive vice president Michael Lytton said the addition of commercial scale soft gel capacity to their full offering of dosage forms, which includes parenteral, solid and liquid technologies, creates a more comprehensive array of options for its clients.
"Soft gel oral drug delivery offers many advantages to some of the more challenging compounds being developed by the pharmaceutical industry today and the collaboration with Procaps builds on Patheon’s successful SoluPath solution set for compounds with solubility challenges,” Lytton added.